Cardiovascular disease, specifically from atherosclerosis, is the major cause of mortality in
SLE in developed countries. In a recent study the investigators have shown that high
sensitivity C reactive protein (hs-CRP) is higher in SLE patients with (versus without)
coronary calcium, a measure of subclinical atherosclerosis. In an ongoing two year
intervention trial of atorvastatin, the investigators will determine if statins retard
coronary calcium and reduce hs-CRP. However, 10% of the patients in the trial were intolerant
of statins. The investigators want to now investigate whether there are additional, and
potentially safer ways, to reduce hs-CRP in SLE. In this study, the investigators will
determine if doxycycline reduces hs-CRP and other vascular inflammatory markers including
interleukin 6 (IL-6), soluble vascular cell adhesion molecule (sVCAM-1), soluble inter cell
adhesion molecule (s-ICAM-1) and matrix metalloproteinase 9 (MMP-9) in SLE.
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Federal University of São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.